Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis

Mary Lynne Filipi, Jill Beavin, Raquel T. Brillante, Kathleen Costello, Gail C. Hartley, Kay Hartley, Marie Namey, Shirley O'Leary, Gina Remington

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Several interferon beta (IFNβ) formulations are approved for first-line use as disease-modifying therapies to treat patients with multiple sclerosis (MS). Systemic post-injection reactions, often termed flu-like symptoms (FLS), occur in approximately half of all patients treated with IFNβs and can affect adherence to therapy. These symptoms, which include pyrexia, chills, malaise, myalgia, and headaches, usually resolve within 24 hours or persist intermittently following each injection. Because FLS, which usually occur early in the treatment course and diminish over time, are a primary cause of nonadherence to IFNβ therapy, it is important to employ strategies that can attenuate these side effects. Methods: To identify interventions effective in limiting FLS, a panel of United States-based nurses with expertise in MS patient care was convened and a literature review completed. Results: Panel consensus was reached on specific interventions that can attenuate FLS. These prevention and mitigation strategies include dose titration, analgesia, and optimal injection timing, as well as other techniques that panel members have found useful in their clinical practice experience. Conclusions: These measures, in addition to effective patient education, will help to reduce the incidence of FLS secondary to IFNβ therapy, improve patient medication adherence, and positively affect long-term clinical outcomes.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalInternational Journal of MS Care
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Interferons
Multiple Sclerosis
Nurses
Interferon-beta
Injections
Therapeutics
Chills
Medication Adherence
Myalgia
Patient Education
Patient Compliance
Analgesia
Headache
Consensus
Patient Care
Fever
Incidence

ASJC Scopus subject areas

  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Filipi, M. L., Beavin, J., Brillante, R. T., Costello, K., Hartley, G. C., Hartley, K., ... Remington, G. (2014). Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. International Journal of MS Care, 16(1), 55-60. https://doi.org/10.7224/1537-2073.2013-006

Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. / Filipi, Mary Lynne; Beavin, Jill; Brillante, Raquel T.; Costello, Kathleen; Hartley, Gail C.; Hartley, Kay; Namey, Marie; O'Leary, Shirley; Remington, Gina.

In: International Journal of MS Care, Vol. 16, No. 1, 01.01.2014, p. 55-60.

Research output: Contribution to journalArticle

Filipi, ML, Beavin, J, Brillante, RT, Costello, K, Hartley, GC, Hartley, K, Namey, M, O'Leary, S & Remington, G 2014, 'Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis', International Journal of MS Care, vol. 16, no. 1, pp. 55-60. https://doi.org/10.7224/1537-2073.2013-006
Filipi, Mary Lynne ; Beavin, Jill ; Brillante, Raquel T. ; Costello, Kathleen ; Hartley, Gail C. ; Hartley, Kay ; Namey, Marie ; O'Leary, Shirley ; Remington, Gina. / Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. In: International Journal of MS Care. 2014 ; Vol. 16, No. 1. pp. 55-60.
@article{6426618b62ad4e96ac0c3749dfab4b4f,
title = "Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis",
abstract = "Background: Several interferon beta (IFNβ) formulations are approved for first-line use as disease-modifying therapies to treat patients with multiple sclerosis (MS). Systemic post-injection reactions, often termed flu-like symptoms (FLS), occur in approximately half of all patients treated with IFNβs and can affect adherence to therapy. These symptoms, which include pyrexia, chills, malaise, myalgia, and headaches, usually resolve within 24 hours or persist intermittently following each injection. Because FLS, which usually occur early in the treatment course and diminish over time, are a primary cause of nonadherence to IFNβ therapy, it is important to employ strategies that can attenuate these side effects. Methods: To identify interventions effective in limiting FLS, a panel of United States-based nurses with expertise in MS patient care was convened and a literature review completed. Results: Panel consensus was reached on specific interventions that can attenuate FLS. These prevention and mitigation strategies include dose titration, analgesia, and optimal injection timing, as well as other techniques that panel members have found useful in their clinical practice experience. Conclusions: These measures, in addition to effective patient education, will help to reduce the incidence of FLS secondary to IFNβ therapy, improve patient medication adherence, and positively affect long-term clinical outcomes.",
author = "Filipi, {Mary Lynne} and Jill Beavin and Brillante, {Raquel T.} and Kathleen Costello and Hartley, {Gail C.} and Kay Hartley and Marie Namey and Shirley O'Leary and Gina Remington",
year = "2014",
month = "1",
day = "1",
doi = "10.7224/1537-2073.2013-006",
language = "English (US)",
volume = "16",
pages = "55--60",
journal = "International Journal of MS Care",
issn = "1537-2073",
publisher = "Consortium of Multiple Sclerosis Centers (CMSC)",
number = "1",

}

TY - JOUR

T1 - Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis

AU - Filipi, Mary Lynne

AU - Beavin, Jill

AU - Brillante, Raquel T.

AU - Costello, Kathleen

AU - Hartley, Gail C.

AU - Hartley, Kay

AU - Namey, Marie

AU - O'Leary, Shirley

AU - Remington, Gina

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Several interferon beta (IFNβ) formulations are approved for first-line use as disease-modifying therapies to treat patients with multiple sclerosis (MS). Systemic post-injection reactions, often termed flu-like symptoms (FLS), occur in approximately half of all patients treated with IFNβs and can affect adherence to therapy. These symptoms, which include pyrexia, chills, malaise, myalgia, and headaches, usually resolve within 24 hours or persist intermittently following each injection. Because FLS, which usually occur early in the treatment course and diminish over time, are a primary cause of nonadherence to IFNβ therapy, it is important to employ strategies that can attenuate these side effects. Methods: To identify interventions effective in limiting FLS, a panel of United States-based nurses with expertise in MS patient care was convened and a literature review completed. Results: Panel consensus was reached on specific interventions that can attenuate FLS. These prevention and mitigation strategies include dose titration, analgesia, and optimal injection timing, as well as other techniques that panel members have found useful in their clinical practice experience. Conclusions: These measures, in addition to effective patient education, will help to reduce the incidence of FLS secondary to IFNβ therapy, improve patient medication adherence, and positively affect long-term clinical outcomes.

AB - Background: Several interferon beta (IFNβ) formulations are approved for first-line use as disease-modifying therapies to treat patients with multiple sclerosis (MS). Systemic post-injection reactions, often termed flu-like symptoms (FLS), occur in approximately half of all patients treated with IFNβs and can affect adherence to therapy. These symptoms, which include pyrexia, chills, malaise, myalgia, and headaches, usually resolve within 24 hours or persist intermittently following each injection. Because FLS, which usually occur early in the treatment course and diminish over time, are a primary cause of nonadherence to IFNβ therapy, it is important to employ strategies that can attenuate these side effects. Methods: To identify interventions effective in limiting FLS, a panel of United States-based nurses with expertise in MS patient care was convened and a literature review completed. Results: Panel consensus was reached on specific interventions that can attenuate FLS. These prevention and mitigation strategies include dose titration, analgesia, and optimal injection timing, as well as other techniques that panel members have found useful in their clinical practice experience. Conclusions: These measures, in addition to effective patient education, will help to reduce the incidence of FLS secondary to IFNβ therapy, improve patient medication adherence, and positively affect long-term clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84898614240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898614240&partnerID=8YFLogxK

U2 - 10.7224/1537-2073.2013-006

DO - 10.7224/1537-2073.2013-006

M3 - Article

VL - 16

SP - 55

EP - 60

JO - International Journal of MS Care

JF - International Journal of MS Care

SN - 1537-2073

IS - 1

ER -